Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: other routes
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study report meets generally acceptable scientific principles

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1969
Report date:
1969

Materials and methods

Principles of method if other than guideline:
Study to determine the acute i.p. toxicity ot the test substance in mice
GLP compliance:
no

Test material

Constituent 1
Reference substance name:
Ethanol, 2,2'-oxybis-, reaction products with ammonia, morpholine derivs. residues
EC Number:
272-712-1
EC Name:
Ethanol, 2,2'-oxybis-, reaction products with ammonia, morpholine derivs. residues
Cas Number:
68909-77-3
Molecular formula:
Not applicable (UVCB)
IUPAC Name:
2-(2-hydroxyethoxy)ethan-1-ol; 2-[1-(morpholin-4-yl)ethoxy]ethan-1-amine; 2-{2-[bis(2-hydroxyethyl)amino]ethoxy}ethan-1-ol; 4-{2-[2-(morpholin-4-yl)ethoxy]ethyl}morpholine; morpholin-3-one
Details on test material:
- Name of test material (as cited in study report): Morpholin-Rueckstand (morpholin remainder)
- Substance type: remainder mixture
- Physical state: liquid
- Analytical purity: no data

Test animals

Species:
mouse
Strain:
not specified
Sex:
male/female

Administration / exposure

Route of administration:
intraperitoneal
Vehicle:
water
Details on exposure:
2%-20%
Doses:
200-1600 µL/kg (=ca. 212-1700 mg/kg; calculated with a density of 1.06 g/mL)
No. of animals per sex per dose:
10
Control animals:
no
Details on study design:
- Duration of observation period following administration: 7 days

Results and discussion

Effect levels
Sex:
male/female
Dose descriptor:
LD50
Effect level:
ca. 742 mg/kg bw
Remarks on result:
other: original data: ca. 0.7 mL/kg bw
Mortality:
no mortality up to 400 µL/kg bw
500 µL/kg bw: 2/20
640 µL/kg bw: 3/20
800 and 1600 µL/kg bw: 20/20
Clinical signs:
800 and 1600 µL/kg bw: directly after injection tremor, convulsion, stretching, crying, sunken flanks, high stepping and slightly staggering gait, avoidance of abdominal position, agitation, closed eye lids; intense stretching convulsions in agony
<= 640 µL/kg bw: symptoms as decribed for higher doses but in weaker extension; reversible within at least 6 days
Body weight:
not measured at study termination
Gross pathology:
Animals that died: Intestines filled with bloody liquids, lobular pataatern visible;4* intraabdominal adhesions
Sacrificed animals: in most of the animals intrabdominal adhesions, 12* truncated liver edges

Applicant's summary and conclusion